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Dimitris K. Grammatopoulos
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CRH targets the human myometrium during pregnancy. The
efficiency of CRHactions is determined by expression of func-
tional receptors (CRH-R), which are dynamically regulated.
Studies in myometrial tissue biopsies using quantitative RT-
PCR demonstrated that the onset of labor, term or preterm, is
associated with a significant 2- to 3-fold increase in CRH-R1
mRNA levels. Detailed analysis of myometrial CRH-R1 mRNA
variants showed a decline of the pro-CRH-R1mRNA encoding
theCRH-R1 variant during labor and increasedmRNA levels
of CRH-R1d mRNA. Studies in myometrial cells identified
IL-1 as an important regulator of myometrial CRH-R1 gene
expression because prolonged treatment of myometrial cells
with IL-1 (1 ng/ml) for 18 h induced expression of CRH-R1
mRNA levels by 1.5- to 2-fold but significantly attenuated
CRH-R1mRNA expression by 70%. In contrast, IL-1 had no
effect on CRH-R1d mRNA expression. Studies using specific
inhibitors suggest that ERK1/2, p38 MAPK, and downstream
nuclear translocation of nuclear factor-B mediate IL-1 ef-
fects on myometrial CRH-R1 gene. However, the increased
CRH-R1 mRNA expression was associated with a dampening
of the receptor efficacy to activate the adenylyl cyclase/cAMP
signaling cascade. Thus, our findings suggest that IL-1 is an
important regulator of CRH-R1 expression and functional ac-
tivity, and this interaction might play a role in the transition
of theuterus fromquiescence toactive contractionsnecessary
for the onset of parturition. (Endocrinology 148: 3205–3213,
2007)
DURING GESTATION, THE uterus remains in a state ofquiescence while the fetus matures. At term, delivery
is facilitated by cervical dilatation and a switch of the uterus
from quiescence to a state of coordinated contractility (1). In
humans, the mechanism of parturition involves multiple
pathways, and some are regulated by “stress” peptides, in
particular placental CRH. The plasma concentrations of CRH
increase exponentially as pregnancy progresses toward labor
andmay act as a predictor of the duration of human gestation
(2).
The precise biological function of CRH and the family of
CRH-related peptides, urocortins, during pregnancy are not
well defined, but they appear to play important roles in
regulation of myometrial contractility (3). The human myo-
metrium expresses a plethora of CRH and CRH-related pep-
tides and their respective receptors R1 and R2 (4). Current
evidence suggests that CRH-R1- and CRH-R2-activated sig-
naling pathwaysmight exert distinct actions in the regulation
of myometrial contractility (4). The myometrial CRH-Rs ex-
hibit increased affinity for CRHduring pregnancy (5) and, on
agonist activation, stimulate cAMP and cGMP production
and nitric oxide synthase up-regulation (6), thus promoting
myometrial quiescence, possibly though activation of
CRH-R1 receptors. Recent isometric contractility studies in
myometrial tissue strips have confirmed the ability of CRH
to relax the human pregnant myometrium (7). In contrast,
CRH-R2-specific agonists such as urocortin-II can activate
ERK1/2 and RhoA pathways that actively promote myome-
trial contractility (8). Furthermore, progression of human
pregnancy toward term and active labor is associated with
activation of intracellular mechanisms involving uterotonin-
activated protein kinase C that reduce the myometrial re-
sponsiveness to CRH, an effect mediated through phosphor-
ylation and desensitization of specific CRH-R variants (9, 10).
The human CRH-R1 gene spans over a 50.3-kb region and
contains 14 exons (11); translation of all exons results in a
human-specific, 444-amino acid seven-transmembrane do-
main protein receptor, termed CRH-R1, which exhibits im-
paired agonist binding and signaling properties. Deletion of
exon 6 results in expression of CRH-R1mRNA,which is the
main functional CRH-R1 receptor variant and contains 415
amino acids. Therefore, the CRH-R1 can be considered as
a “pro-CRH-R1” receptor variant. The CRH-R1 gene appears
to be subject to significant alternative splicing, and a growing
number of CRH-R1 mRNA splice variants have been de-
scribed, termed R1c–R1n (11). All of these variants have exon
6 spliced out together with other deletions. At least four
distinct CRH-R1 mRNA variants (, , c, and d) have been
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identified in human myometrium during pregnancy (12);
progression toward term is associated with altered expres-
sion of myometrial CRH-Rs and the appearance of CRH-R1
variants such as the R1d, with reduced signaling abilities
(13). This might have important functional consequences by
dampening tissue responsiveness to CRH actions.
The mechanisms regulating myometrial CRH-R1 expres-
sion are not well understood. The CRH-R1 promoter con-
tains, among others, nuclear factor-B (NF-B) putative rec-
ognition elements (Bs) elements (14). Accumulating
evidence points toward a role for NF-B and its major acti-
vator IL-1 in the physiology and pathophysiology of labor
(15), because myometrial IL-1 and NF-B activity increases
with labor onset and is central tomultiple prolabor pathways
by stimulating prostaglandin-endoperoxide synthase 2
(PTGS2) expression and prostaglandin (PG) synthesis (16). In
this study, we examined the levels of expression of CRH-R1
and specific CRH-R1 variants by using quantitative RT-PCR
analysis from myometrial biopsies obtained preterm and
term, before and after the onset labor aswell as the regulation
of CRH-R1 expression and activity by IL-1 in human preg-
nant myometrial cells.
Materials and Methods
Subjects and myocytes culture preparations
Pregnant myometrial biopsies were obtained from women undergo-
ing elective cesarean section preterm (30–35 wk of gestation; n  12) or
at term (37 wk of gestation; n  12) before (n  6) or after (n  6) the
onset of labor for nonmaternal problems.Active laborwas demonstrated
by regular uterine contractions and ripe cervix, with dilation more than
4 cm (range of 4–7 cm;mean of 5.4 cm). The biopsy sitewas standardized
to the upper margin of the lower segment of the uterus in the midline.
This provides the closest approximation to the upper segment of the
uterus. The biopsies were immediately snap frozen in liquid nitrogen
and subsequently stored at 70 C until use or processed immediately
for myocyte cell culture as described previously (10). The age range was
25–35 yr for both groups. Ethical approval was obtained from the local
ethical committee, and informed consent to the studywas obtained from
all patients.
The myometrial smooth muscle cells were cultured in DMEM con-
taining 10% fetal calf serum, 1% l-glutamine, 200 IU/ml penicillin, 200
mg/ml streptomycin, at 37 C in a humidified atmosphere of 95% air and
5% CO2 until confluency. Cells were trypsinized in 0.25% trypsin con-
taining 0.02% EDTA in Hanks’ balanced salt solution and cultured in
12-well plates for protein and in six-well plates for mRNA extraction. At
18 h before treatments, the cells were transferred in DMEM without
l-glutamine, fetal calf serum, and antibiotics. The following day, cells
were treated with IL-1 (1 ng/ml) for various time intervals (2–18 h). In
some experiments, cells with pretreated with or without specific inhib-
itors, as follows: 10mU0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-amino-
phenylmercapto)butadiene] (2 h) [U0126 inhibits both active and inac-
tive MAPK kinase (MEK1/2)], 10 m SB203580 [4-(4-fluorophenyl)-2-
(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole] (1 h) (SB203580 is
a selective inhibitor of p38 MAPK, which acts by competitively inhib-
iting ATP binding), 25 m IB kinase (IKK) inhibitor II, Wedelolactone
(4 h) (IKK inhibitor II is a selective and irreversible inhibitor of IKK and
 kinase activity; it inhibits NF-B-induced gene transcription by block-
ing the phosphorylation and degradation of IB). Proteins and RNA
were harvested as described below. For confocal microscopy experi-
ments, serum-deprived cells were stimulated with 1 ng/ml IL-1 for 30
and 60 min. The purity of myometrial muscle cells was assessed by
immunocytochemical staining for -actin with mouse monoclonal an-
tibody specific for smooth muscle -actin (Sigma, Gillingham, UK).
Confluent cells up to third passage were used; no significant difference
between results were obtained with cells from individual passages and
cells obtained from different myometrial biopsies.
Chemicals
CRH was purchased from Bachem (Merseyside, UK). IL-1 and the
inhibitors (U0126, MEK1/2 inhibitor; SB203580, p38 inhibitor; and IKK
inhibitor II, Wedelolactone) were fromMerck Biosciences (Nottingham,
UK). Antibodies (CRH-R, p65, IB, and PTGS2) were from Santa Cruz
Biotechnology (Santa Cruz, CA); glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) antibody was from BioGenesis (Bournemouth, UK);
secondary antibodies were fromDakoCytomation (Eye, UK); Alexa Flu-
or594, Alexa Fluor488-phalloidin, and Slowfade gold antifade reagent
with 4,6-diamidino-2-phenylindole (DAPI) were from Invitrogen
(Carlsbad, CA). Vectashield Hard Set TM mounting medium for fluo-
rescence was from Vector Laboratories (Burlingame, CA). Mounting
solution without DAPI was from Vector Laboratories (Peterborough,
UK). Cell culture media were from Invitrogen. RNasin, avian myelo-
blastosis virus, random hexamers, and oligo-dTTP were from Promega
(Madison, WI), and dNTPs, Taq polymerase, and DNA ladder were
purchased from Bioline (London, UK). SYBR Green I and PCR mixture
for quantitative PCR was from BioGene (Kimbolton, UK). Primers were
purchased from TANG (Gateshead, UK). All other chemicals were pur-
chased from Sigma.
RNA extraction and real-time and conventional RT-PCR
RNA extraction was performed by using GeneElute Mammalian To-
tal RNA kit (Sigma), according to the instructions of the manufacturer.
The purity and concentration of total RNA was determined spectro-
scopically. RNA, 500 ng, was used for cDNA synthesis, in a total volume
of 50 l RT reaction. Total RNA was heated up to 70 C for 5 min before
the addition of random hexamers (Promega) and reverse transcriptase
containing an RNase inhibitor (Fermentas, York, UK). The reaction mix-
ture was incubated at 42 C for 60 min, followed by an additional 10 min
incubation at 70 C.
Quantitative (real-time) PCR of PTGS2 was performed on a Roche
Light Cycler system (Roche Molecular Biochemicals, Mannheim, Ger-
many). The PCR was performed in a 10 l reaction mixture containing
5 l of PCR 2Mastermix with 2mmMgCl2, 0.5 l of Light Cycler DNA
Master SYBR Green I, 1 l of each primer (2 ng/l), and 1 l of cDNA.
The PCR protocol consisted of a denaturation step at 95 C for 15 sec,
followed by 40 cycles of amplification at 95 C for 5 sec, 58 C for 10 sec,
and 72 C for 15 sec, and finally by a melting-curve analysis step at 95
C for 0 sec, 56 C for 15 sec, and 99 C for 0 sec. For analysis, quantitative
amounts of gene of interest were standardized against the housekeeping
gene -actin. The sequence of PTGS2 mRNA primers used were as
follows: forward, 5-TTCAAATGAGATTGTGGGAAAATTGCT-3; and
reverse, 5-AGATCATCTCTGCCTG AGTATCTT-3. The -actin prim-
ers were as follows: forward, 5-AAGAGAGGCATCCTCACCCT-3;
and reverse, 5-TACATGGCTGGGGTGTTGAA-5. As negative con-
trols, preparations lacking RNA or reverse transcriptase were used.
RNA expression was tested in four independent experiments. The
mRNA levels were expressed as a ratio, using the “ method” for com-
paring relative expression between treatments. The PCR products were
sequenced in an automated DNA sequencer (Department of Biological
Sciences, TheUniversity ofWarwick,Warwick,UK), and the sequence data
were analyzed using Blast Nucleic Acid Database Searches from the Na-
tional Center for Biotechnology Information.
Quantitative PCR on a TaqMan Gene Expression Assay (Applied
Biosystems, Warrington, UK) was also used to determine expression
levels of various CRH-R1 mRNA variants in human gestational myo-
metrium and human primary myometrial cells. Briefly, four sets of
oligonucleotide primers and four TaqMan probes specific for various
human CRH-R1 mRNAs were designed from the GenBank database by
mySciences (Applied Biosystems). The first primers/probe combination
used amplified a sequence overlapping exons 8–9, which is present in
all known CRH-R1 variants detected in the human myometrium, R1,
R1, R1c, and R1d (12). Therefore, the PCR product reflected total
CRH-R1 mRNA variant expression and was designated as CRH-R1T. In
addition, primers and fluorescent probes specific for exon 6 (found in
R1 mRNA variant only) were designed, and the PCR amplification
product was designated as CRH-R1. Similarly, primers and probes
overlapping exons 2–4 and 12–14 were designed to amplify sequences
specific for CRH-R1c and CRH-R1d (Fig. 1). Real-time RT-PCRs were
performed using the ABI PRISM 7000 Sequence Detection System (Ap-
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plied Biosystems) in a total volume of 30 l reaction mixture following
the protocol of the manufacturer, using the SYBR Green Universal 2
PCRMaster Mix (Applied Biosystems) and 0.1 m of each primer using
the dissociation protocol for the amplification of CRH-R1 mRNA vari-
ants. Negative controls containing water instead of first-strand cDNA
were also used. Each sample was normalized on the basis of its 18S
ribosomal RNA content (housekeeping gene). The 18S quantification
was performed with a TaqMan ribosomal RNA reagent kit (Applied
Biosystems) using the protocol of the manufacturer. All samples were
run in triplicate, and results were calculated with reference to the am-
plification of 18S rRNA using comparative threshold cycle (CT) method
for relative quantitation (ABI Prism 7000 SDS version 1.1 software;
Applied Biosystems).
The results were expressed as mean  se. Relative gene expression of
targetmRNAwasnormalized to a calibrator thatwas chosen to be the basal
condition (untreated sample). Resultswere calculatedwith theCTmeth-
od; theywere expressed as then-folddifferences in gene expression relative
to 18S rRNA and calibrator and were determined as follows: n-fold 
2
(CT sample  CT calibrator), where the parameter CT is defined as the fractional
cyclenumberatwhich thePCRreporter signalpassesa fixed threshold.CT
values of the sample and calibrator were determined by subtracting the
average CT value of the transcript under investigation from the average CT
value of the 18S rRNA gene for each sample.
Qualitative RT-PCR analysis
The conditions for the conventional (qualitative) RT-PCR of CRH-R1
mRNA were as follows: 95 C for 15 sec, 64 C for 15 sec, and 72 C for 30
sec, in a total of 35 cycles with a final extension step at 72 C for 7 min.
Primers sequence were as follows: forward, 5-CAAACAATGGCTAC-
CGGGAG-3; and reverse, 5ACACCCCAGCCAATGCAGA-3. These
primers amplified a 475-bpDNA fragment present in all CRH-R1mRNA
variants except CRH-R1 and a 538-bp DNA fragment specific for CRH-
R1. Ten microliters of the reaction mixture were subsequently elec-
trophoresed on a 1.2% agarose gel and visualized by ethidium bromide,
using a 1-kb DNA ladder (Invitrogen) to estimate the band sizes. As a
negative control for all of the reactions, distilled water was used in place of
the cDNA. The PCR products were sequenced in an automated DNA
sequencer (Department of Biological Sciences, TheUniversity ofWarwick),
and the sequence data were analyzed using Blast Nucleic Acid Database
Searches from the National Center for Biotechnology Information.
Western blot
Cells were lysed in 150 l Laemmli’s buffer. The lysates were soni-
cated for 30 sec, and, after boiling for 5 min, proteins were spun down
and 15 l of the supernatant was loaded on 10%SDS-polyacrylamide
gels. Gels were run at 200 V for approximately 1 h. Proteins were
electrophoretically transferred to a polyvinylidene difluoride filter at 100
V for 1 h. The filters was initially incubated in Tris-buffered saline (TBS)
containing 0.1% Tween 20 (TBS-T) and 5%milk (wt/vol) for 1 h at room
temperature and, after a brief wash with TBS-T, were incubated with
primary antisera. The primary antibodies for PTGS2 and CRH-R1/2
were used at a 1:1000 dilution in TBS-T overnight at 4 C (CRH-R1/2) or
at room temperature for 1 h (PTGS2), whereas the IB antibody was
used at a 1:500 dilution (overnight at 4 C). Equal protein loading was
confirmed by using anti-GAPDH antibodies (1:40,000 dilution in TBS-T
at room temperature for 1 h). The filters were washed thoroughly for 30
min with TBS-T, before incubation with the appropriate horseradish
peroxidase-conjugated secondary antibodies (1:2000) for 1 h at room
temperature. After an additional washing step for 30 min with TBS-T,
antibody complexes were visualized using enhanced chemilumines-
cence. In some experiments, IB and GAPDH probed blots were in-
cubated with goat antirabbit IRDye 800-conjugated IgG at 1:6000 in 10
ml of blocking buffer with gentle agitation for 1 h at room temperature.
Finally, the blot was washed two more times each with 15 ml of TBS-T
and once with TBS only. The membrane was dried, visualized, and
analyzed on the Odyssey Infrared Imaging System (LI-COR Biosciences,
Cambridge, UK).
Measurement of cAMP production
Myometrial cells were plated in 12-well plates, and, when they
reached 70–80% confluency, they were transferred in DMEM for 12 h
and treated with 1ng/ml IL-1 for 18 h. At the end of the incubation
period, media was aspirated and cells were washed with plain DMEM.
Then, stimulation buffer (DMEM containing 10mmMgCl2 and 1mg/ml
3-isobutyl-1-methylxanthine, a phosphodiesterase inhibitor) was added
and cells were incubated for 20 min at 37 C. After washing with 1 ml
DMEM, cells were stimulated with 100 nm CRH or 10 m forskolin (to
induce direct adenylyl cyclase activation) for 15 min. The reaction was
stopped by adding 10 l of concentrated HCl for 15–20 min at room
temperature. Subsequently, cells were scraped and transferred in 1.5 ml
tubes. After a brief spin, lysates were stored at 20 C. The cAMP levels
were determined by a commercially available ELISA kit (low pH) from
R & D Systems (Minneapolis, MN).
Confocal microscopy
Myocytes were grown on aminopropylethoxysilane-treated glass
coverslips. To monitor NF-B(p65) translocation, serum-deprived cells
were treated with 1 ng/ml IL-1 for 30–60 min and fixed with 4%
paraformaldehyde in PBS. After permeabilization with PBS containing
0.01% Triton X-100 and 3% BSA, cells were incubated with p65 antibody
(1:100) overnight at 4 C. After three brief washes with PBS, slides were
incubated for 1 h at room temperature with 1:400 antirabbit Alexa
Fluor594. After three washes with PBS, the slides were mounted with
Vectashield Hard Set TM mounting medium for fluorescence (Vector
Laboratories, Burlingame, CA) or Slowfade gold antifade reagent with
DAPI (Invitrogen). For detection of CRH-R, fixed cells were incubated
with 1:100 CRH-R1/2 antibody overnight in the presence or absence of
1 m blocking peptide. On the following day, the slides were washed
and incubated with Alexa Fluor594 and Alexa Fluor488-phalloidin. The
slides were mounted as described above. The slides were examined
under an oil immersion objective (63) using a Leica (Deerfield, IL)
DMRE laser scanning confocal microscope with TCS SP2 scan head.
FIG. 1. Schematic diagram of CRH-R1 gene splicing pattern and the annealing position of PCR primers and real-time PCR probes relative to
the structure of CRH-R1 alternative spliced variants. Arrows indicate annealing position of primers. The qualitative RT-PCR forward primer
was designed to span across exons 3 and 4; thus, annealing to CRH-R1c sequence was not possible.
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Data analysis and statistical methods
Results from triplicate experiments were pooled and analyzed by
one-way ANOVA with Student-Newman-Keuls multiple comparison
methods, using SigmaStat version 3.0 (SPSS, Chicago, IL).
Results
Determination of myometrial CRH-R1 mRNA variant
expression
Previous studies (12) using qualitative RT-PCR analysis
for CRH-R1 mRNA variants identified R1, R1, and R1c
mRNA to be present in both preterm and term pregnant
myometrium, whereas R1d mRNA was only present in
term myometrium. Quantitative analysis of RNA isolated
from human pregnant (term and preterm) myometrium
with amplified CRH-R1 (total) mRNA-specific sequences
showed a low number of CT (30–32 cycles), indicative of
substantial levels of CRH-R1T mRNA. CRH-R1 and R1c
as well as R1d were also amplified from both term and
preterm myometrium (reflecting probably the higher sen-
sitivity and specificity of the quantitative RT-PCR method
used); however, the CT values of these variants mRNA
amplification were higher (33–35 cycles), suggesting lower
levels of expression (data not shown). Furthermore, com-
parison of the mRNA concentrations showed that the ex-
pression levels of the CRH-R1 mRNA variants relative to
the total CRH-R1T mRNA levels was 4% for the R1, 1%
for the R1c, and 20% for the R1d. These data suggest that
the majority of CRH-R1TmRNA amplification signal prob-
ably reflects CRH-R1 mRNA levels expressed in human
myometrium (CRH-R1T). These ratios cannot be used for
an accurate quantitation of each CRH-R1 mRNA levels but
can rather provide a relative estimation of comparative
receptor variant expression.
Studies on human preterm nonlaboring, preterm laboring,
term nonlaboring, or term laboring human myometrium
(n  6 for each group) showed that the expression of both
CRH-R1T and CRH-R1 mRNAs were significantly higher
(by 2.5- and 0.5-fold, respectively) in term compared with
preterm nonlaboring myometrium (Fig. 2A). In contrast,
CRH-R1c and R1d mRNAs were not altered (Fig. 2A). Fur-
thermore, active labor in both preterm and term groups was
associated with a significant increase (by 3- and 2-fold, re-
spectively) of CRH-R1T mRNA and CRH-R1d mRNA (by
2.5- and 3.5-fold, respectively). In contrast, CRH-R1mRNA
showed a significant decrease (by 40 and 70%, respectively)
in laboring myometrium (both preterm and term) compared
with nonlaboring myometrium, whereas no change was ob-
served in CRH-R1c mRNA levels (Fig. 2B).
CRH-R mRNA and protein expression in primary
myometrial smooth muscle cells
The differential expression levels of CRH-R1 mRNA
transcripts in human myometrial biopsies during labor
was further investigated in primary myometrial smooth
muscle cells. Qualitative RT-PCR studies confirmed the
expression of multiple CRH-R1 (including CRH-R1) mR-
NAs (Fig. 3A). Moreover, indirect immunofluorescence
with a CRH-R1/2-specific antibody was used to monitor
distribution of CRH-R and counterstaining with phalloi-
din to detect filamentous actin (F-actin) stress fibers and
the nuclear stain DAPI. Confocal microscopy studies dem-
onstrated a strong CRH-R-positive immunostaining in the
plasma membrane and the cytoplasm (Fig. 3B); interest-
ingly, the plasma membrane signal was not evenly dis-
tributed in the cell membrane and was confined in specific
membrane areas. Also, apparent colocalization between
the CRH-R and F-actin immunostaining was observed in
the plasma membrane (Fig. 3B, yellow), potentially sug-
gestive of some common subcellular localization of CRH-R
and actin stress fibers. No staining was detectable in cells
in which the primary anti-CRH-R antibody was omitted or
when cells were preincubated with a specific CRH-R an-
tibody-blocking peptide (Fig. 3C).
FIG. 2. Comparative studies of expression levels of CRH-R1mRNA variants in gestational myometrial tissues (n 6 for each group) in relation
to progression toward term (A) or the onset of labor (preterm or term) (B). Relative expressionwas determined by real-time quantitative RT-PCR
(TaqMan; Applied Biosystems). Amplification runs in triplicate were performed with cDNA preparations reversibly transcribed in the same
reaction from 500 ng total RNA in each case. Results are expressed asmean values SEM of relativemRNA expression levels normalized against
the levels of the housekeeping gene 18S RNA. *, P  0.05 compared with preterm nonlaboring (A) or nonlaboring (B) myometrium values. The
mean results of nonlaboring preterm myometrium (A) or nonlaboring preterm and term (B) were arbitrarily assigned the value 1. NL,
Nonlaboring; L, laboring.
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Effects of IL-1 on CRH-R1 and PTGS2 mRNA and protein
expression in primary myometrial smooth muscle cells
It is well established that proinflammatory cytokines,
especially IL-1, are important regulators of myometrial
smooth muscle cell gene expression during pregnancy
(17). To confirm the functional activity of IL-1 in these
cells, preliminary experiments were performed in cells
treated with IL-1 for various time intervals, and expres-
sion levels of both PTGS2 mRNA and protein were de-
termined by quantitative RT-PCR and immunoblot anal-
ysis using a specific antibody. Results (data not shown)
showed that exposure of myometrial smooth muscle cells
to IL-1 (1 ng/ml) significantly up-regulated PTGS2
mRNA and protein levels in a time-dependent manner;
IL-1 significantly increased PTGS2 mRNA after 2 h of
incubation and achieved maximal responses after 18 h
(300- and 140-fold increase in mRNA and protein levels,
respectively). Moreover, IL-1 treatment for 18 h induced
myometrial cell CRH-R1T mRNA expression by 3-fold
but significantly attenuated myometrial CRH-R1 mRNA
expression by 40% (Fig. 4), without affecting CRH-R1c
(data not shown) or R1d mRNA levels (Fig. 4). Further-
more, IL-1 treatments for 2 or 6 h had no effect on myo-
metrial cell CRH-R1 (total), CRH-R1, and CRH-R1d
mRNA expression levels (Fig. 4). The effect of IL-1 was
dose dependent, and a small but significant effect (0.8-fold
increase above basal) on CRH-R1 mRNA was observed
when IL-1 (0.1 ng/ml) was used (data not shown). In-
creasing concentrations of IL-1 up to 10 ng/ml did not
exert any additional induction of CRH-R1 mRNA levels
(data not shown).
Signaling pathways mediating IL-1 effects in myometrial
cells
NF-B is a major key intermediate of IL-1 actions in
myometrial cells (15). Confocal microscopy studies using a
specific p65 (RelA) antibody (Fig. 5A) demonstrated that, in
untreated cells, p65 immunoreactivitywas exclusively found
in the cytoplasm. The potential role of NF-B on IL-1-in-
duced PTGS2 and CRH-R1 mRNA variant expression was
FIG. 4. Time course of the IL-1 effect on CRH-R1 (total), CRH-R1,
andCRH-R1dmRNA level in humanmyometrial smoothmuscle cells.
Cells isolated from myometrium of nonlaboring women (n  6) were
treated with IL-1 (1 ng/ml) for various time intervals, and target
mRNAwere determined by real-time quantitative RT-PCR (TaqMan;
Applied Biosystems) as described inMaterials andMethods. Data are
expressed as mean values  SEM of relative mRNA expression levels
normalized against 18S RNA. *, P  0.05 compared with basal (un-
treated). The mean results of basal untreated mRNA concentrations
were arbitrarily assigned the value 1.
FIG. 3. A, RT-PCR amplification of CRH-R1 variants sequences from RNA extracted from primary human myometrial cell cultures. Specific
primers able to amplify CRH-R1, R1, and R1dmRNAwere used as described inMaterials andMethods. Primer sets were designed to amplify
a 475-bp fragment, present in CRH-R1 and R1d (but not R1c) mRNA, or a 538-bp fragment, present in CRH-R1mRNA. PCR products were
resolved on 1.2% agarose gel and stainedwith ethidiumbromide. The identities of the fragmentswere confirmed by direct nucleotide sequencing.
B and C, Visualization of CRH-R distribution in human pregnant myometrial cells by indirect immunofluorescence confocal microscopy using
specific primary antibodies for CRH-R and Alexa Fluor594 secondary antibody (red) in the presence or absence of CRH-R blocking peptide (1
M) as described in Materials and Methods. Distribution of F-actin and stress fibers was also monitored by double staining with Alexa
Fluor488-phalloidin (green). Cell nuclei were stained with the DNA-specific dye DAPI (blue). Identical results were obtained from six inde-
pendent experiments.
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investigated. Exposure ofmyometrial cells to IL-1 (1 ng/ml)
induced nuclear translocation of p65 within 30 min, a re-
sponse that was sustained for at least 1 h. Furthermore, IL-1
actions induced rapid phosphorylation (indicated by the ap-
pearance of another immunoreactive protein with a slightly
higher molecular weight) and subsequent (almost complete)
degradation of IB, the cytoplasmic protein that retains
NF-B in an inactive form through association and masking
the nuclear localization sequence (15) within 30min. The role
of the upstream IKK was evaluated by the use of a specific
IKK inhibitor II, Wedelolactone (18), and determination of
myometrial IB degradation after IL-1-treatment. Pre-
treatment of cellswith 25mWedelolactone for 4 h abolished
IL-1-induced IB degradation and p65 (RelA) nuclear
translocation (Fig. 5, B and C). Most importantly, the IKK
inhibitor significantly attenuated IL-1-induced up-regula-
tion of both PTGS2 and CRH-R1mRNA expression (Fig. 6A).
Previous investigations have shown that IL-1 effects on
myometrial PTGS2 up-regulation involve members of the
family of MAPKs (19), namely ERK1/2 and p38 MAPK. Our
results also showed that both of these kinases are phosphor-
ylated and activated after acute exposure of myometrial cells
to IL-1 (1 ng/ml) for 10 min (data not shown). The role of
these kinases on IL-1-induced regulation of myometrial
target gene expression was investigated by using U0126
(MEK1/2 inhibitor) and SB203580 (a p38 MAPK inhibitor).
Pretreatment of myometrial cells with each inhibitor signif-
icantly attenuated by 70–85% IL-1 effects on PTGS2 and
CRH-R1 mRNA expression (Fig. 6B).
Effects of IL-1 on CRH-induced myometrial cAMP
response
One of the major signaling pathways mediating CRH ef-
fects in human myometrial cells involves activation of the
Gs-adenylyl cyclase pathway (20). The functional conse-
quences of IL-1-induced myometrial CRH-R1 up-regula-
tion was investigated by pretreatment of cells with IL-1 for
18 h, followed by determination of intracellular cAMP pro-
duction in response to CRH stimulation. Surprisingly, al-
FIG. 5. IL-1-induced activation of the NF-B pathway. A, Human smooth muscle cells isolated from myometrium of nonlaboring women (n
6) were treated with IL-1 (1 ng/ml) for various time intervals, and p65 (RelA) nuclear translocation was monitored by indirect immunoflu-
orescence confocal microscopy using specific primary antibodies for p65 and Alexa Fluor594 secondary antibody (red) as described inMaterials
and Methods. In some experiments (C), cells were pretreated with or without 25 M of the IKK inhibitor II Wedelolactone for 4 h, before IL-1
addition for 1 h. Identical results were obtained from four independent experiments and at least 20 cells were examined in each experiment.
B, Representative Western blots of IB expression of cells stimulated with IL-1 (1 ng/ml) for various time intervals. After cell lysis and
centrifugation, supernatantswere subjected to SDS-PAGEand immunoblotted (IB)with antibodies for IB orGAPDH (protein loading control).
After incubation with horseradish peroxidase-conjugated goat antirabbit antibody, complexes were visualized by enhanced chemiluminescence
(top). Alternatively, immunoreactivity was detected by secondary antibodies conjugated to IRDye 800 (near-IR) and the Odyssey detection
system as described in Materials and Methods (bottom). The data represent the mean  SEM of three estimations from three independent
experiments. In some experiments (bottom), cells were pretreated with or without 25 M of the IKK inhibitor II Wedelolactone for 4 h, before
IL-1 addition for 30 min.
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though IL--treatment increased basal and forskolin-stimu-
lated cAMP levels (by 10- and 2-fold, respectively), it
significantly impaired CRH-induced cAMP production (by
85  7%), suggesting that myometrial CRH-R1 mRNA and
protein up-regulation was not associated with increased
functional activity and cAMP production (Fig. 7).
Discussion
Human pregnancy is associated with changes in the myo-
metrial CRH-R variant expression profile and functional ac-
tivity, consistentwith the important role(s) of CRHandCRH-
related peptides in the control of myometrial transition from
a state of quiescence to one of increased contractility (3, 5, 12,
13, 21). These receptors appeared to contribute to mainte-
nance of myometrial relaxation during pregnancy (7)
through activation of the adenylyl cyclase/cAMP pathway
(21). Our quantitative RT-PCR data clearly demonstrated
that, as pregnancy progresses toward term, there is an in-
creased transcription of the CRH-R1 gene in quiescent myo-
metrial tissue. Most importantly, our results suggest that
mechanisms activating myometrial contractility and labor,
either term or preterm, induce increased transcription of the
CRH-R1 gene and accelerate the (unknown) splicing mech-
anisms involved in the generation of downstream CRH-R1
mRNA splice variants. Analysis of the structural character-
istics of myometrial CRH-R1 variants suggests that there are
at least two distinct levels of splicing events (Fig. 1). Use of
quantitative RT-PCR probes capable of distinguishing be-
tween different mRNA variants allowed us to investigate
expression of individual CRH-R1 mRNA variants. The find-
ing that in laboring myometrium there is decreased mRNA
expression of the pro-CRH-R1 variant CRH-R1with simul-
taneous increase of the “total” CRH-R1 mRNA (that reflects
the mRNA levels of the fully active CRH-R1) and the sig-
naling-deficient variant CRH-R1d suggests induction of the
two splicing events regulating individual expression of
CRH-R1 variants by removing sequentially exons 6 and 13.
These findings expand previous studies using a semiquan-
titative RT-PCR method that showed increased CRH-R1
mRNA expression in the lower myometrial segment, but not
the fundus, in both preterm and term labor (22). Therefore,
it appears that labor is associated with increased levels of
active CRH-R1 receptors; this coupled with a decreased ac-
tivity of the adenylyl cyclase/cAMP pathway might allow
CRH to activate other signaling pathways and exert procon-
tractile effects during the development of labor.
The mechanisms regulating CRH-R1 alternative splicing
are essentially unknown. Studies in keratinocytes suggest
that environmental stimuli such as UV irradiation as well as
intracellular messengers such as cAMP and phorbol esters
can induce CRH-R1 splicing (23). Furthermore, CRH-R het-
erogeneity has been shown previously in humanmyometrial
membrane extracts (24), and the functional activity of some
receptor variants appeared to be differentially regulated by
oxytocin (9, 10). Although the lack of suitable antibodies able
to distinguish between different CRH-R1 variants does not
allow additional investigations at the level of individual pro-
tein expression and functional response, these results
strongly suggest that the CRH-R1 gene transcriptional ac-
FIG. 7. Effect of IL-1 on CRH-induced cAMP production from hu-
man pregnant myometrial cells. Cells were pretreated with IL-1 (1
ng/ml) for 18 h, followed by incubation with 100 nM CRH for 10 min
at 37 C. Given that IL-1 pretreatment affected both basal and for-
skolin-induced adenylyl cyclase activity, results were calculated as
percentage of forskolin-induced cAMP release, which was considered
asmaximum (100%) for each group (treated or untreated). Results are
representative of six separate cell culture preparations. Each point is
the mean  SEM of four estimates. *, P  0.05 compared with basal;
	, P  0. 05 compared with CRH-stimulated values in cells without
IL-1 pretreatment.
FIG. 6. Effect of IKK, ERK1/2, and p38 MAPK inhibitors on IL-1-
induced effects on myometrial PTGS2 and CRH-R1 gene expression.
After pretreatment of cells with Wedelolactone (A) and U0126 and
SB203580 (B) and stimulation with IL-1 (1 ng/ml) for 18 h, RNAwas
extracted, and PTGS2 and CRH-R1mRNA levels were determined by
real-time quantitative RT-PCR [TaqMan (Applied Biosystems) and
Lightcycler (Roche Applied Science), respectively] as described in
Materials and Methods. Data are expressed as mean  SEM values of
relative mRNA expression levels normalized against 18S or GAPDH
RNA. *, P  0.05 compared with inhibitor-untreated values.
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tivity and splicing is specifically targeted by the mechanisms
involved in the onset of labor.
To investigate further the expression of CRH-R1, primary
human myometrial cells were used, obtained from term hu-
man quiescent myometrial biopsies. This cellular system can
provide useful information about themechanisms regulating
myometrial CRH-R expression and activity, although it can-
not accurately reflect changes associated with the onset of
labor because it is likely that cell-culturing conditions may
alter cell phenotype. We were able for the first time to dem-
onstrate uneven distribution of CRH-Rs in the plasma mem-
brane. This finding strongly suggests “hotspots” of receptor
expression, probably reflecting “confined” CRH-R signaling
networks in specific areas. These experiments also showed
significant cytoplasmic staining for CRH-R, potentially in-
dicating newly synthesized unprocessed receptors, internal-
ized mature CRH-R, or cytoplasmic forms of specific CRH-R
variants. Moreover, our in vitro studies in myometrial cells
identified IL-1 as a potential regulator of CRH-R1 gene
transcription and splicing pattern. IL-1, like many other
proinflammatory cytokines, has been proposed to play im-
portant role in the onset of labor and the pathogenesis of
infection-induced preterm labor (25). Our results suggest
that IL-1 can potentially target CRH-R1 gene transcription
and splicing mechanisms targeting exon 6, but not exon 13,
of the CRH-R1 gene; these interactions appeared to involve
two members of the MAPK family of proteins, ERK1/2 and
p38 MAPK. In a variety of cells, these kinases exert their
effects through phosphorylation of p65 and modulation of
the NF-B transcriptional activity (26). NF-B is a critical
component of pathways mediating IL-1 actions in human
myometrium and other feto-maternal tissues (27) and in-
creased p65 (RelA):p50 heterodimer DNA binding has been
demonstrated in laboring myometrium and linked with in-
creased transcriptional activation to specifically modulate
changes in expression of genes critical for myometrial acti-
vation and contraction (28). Our results point toward an
important role for NF-B in IL-1 effects on CRH-R1 gene
regulation and splicing, consistent with the presence of
NF-B recognition elements in the CRH-R1 promoter (14). In
our experimental paradigm, IL-1 action induced phosphor-
ylation of IB through an IKK-mediated mechanism that
releases p65 (RelA) and allows its translocation to the nucleus
(15). Other studies have showed that IL-1 actions on myo-
metrial cells can modulate endothelin B receptor but not
endothelinA receptormRNAandprotein (29); thus, CRH-R1
IL-1 interactions may be part of a much larger transcrip-
tional modification in the myometrial cells.
Surprisingly, increased CRH-R1 gene transcription and
generation of receptor splice variantswas not associatedwith
increased CRH signaling activity. On the contrary, pro-
longed exposure of cells to IL-1 significantly impaired
CRH-induced cAMP production, although the IL-1 pre-
treatment significantly augmented basal adenylyl cyclase
activity, in agreement with previous studies (30). It is likely
that this is directly related to repression of the myometrial
Gs gene by NF-B that has been reported recently (31). The
possibility that IL-1 pretreatment might induce expression
of signaling-deficient variants of CRH-R1 such as R1c and
R1d was excluded by our real-time PCR experiments. Inter-
estingly, the myometrial IL-1/NF-B and cAMP/protein
kinase A (PKA) signaling pathways can interact at multiple
levels; exposure of myometrial cells to IL-1 results in a
significant up-regulation of cAMP-phosphodiesterase (PDE)
4, which is the predominant family of PDEs expressed in
human myometrium (30) through a mechanism involving
prostaglandin E2 (PGE2) production and subsequent cAMP
augmentation. Also, myometrial p65 (RelA) appears to be
specifically associatedwith PKAc (aswell as IB), through
an interaction that potentially involves the phosphorylation
of p65 at serine-536 (28). This association might contributes
to p65 inactive state until the cell is exposed to a p65 inducing
stimuli (e.g. IL1-).
One of the main actions of IL-1 in human myometrium
involves the up-regulation of PTGS2 enzyme and increased
production of PG, such as PGE2 (19). Our previous studies
(20) have shown that short (0.5–2 h) as well as prolonged
(8–18 h) treatments with CRH can attenuate myometrial
PGE2 release, and only the prolonged effect of CRH can be
inhibited by coincubation with IL-1. This coupled with the
findings of the present study might suggest that IL-1 acts
to diminish the CRH-induced cAMP response throughmod-
ulation of CRH-R1 gene transcription and splicing, up-reg-
ulation of PDE4, and/or down-regulation of Gs, thus im-
plicating the myometrial cAMP/PKA pathway in the
inhibition of PGE2 synthesis and release.
In conclusion, we provide conclusive evidence that the
onset of labor (preterm or term) is associated with increased
transcription of the myometrial CRH-R1 gene and altered
splicing events that down-regulate the pro-CRH-R1 mRNA
encoding the R1 variant but up-regulating receptor variants
such as CRH-R1d, downstream of CRH-R1. IL-1 appears
to be one of the signals involved in the regulation of the
CRH-R1 gene through a pathway involving activation of
NF-B, the classical mediator of IL-1 intracellular events, as
well as at least twomembers of theMAPK family of proteins,
ERK1/2 and p38 MAPK. Most importantly, IL-1 actions
lead to dampening of the CRH-induced cAMP response, an
event that might contribute to the procontractile intracellular
environment required for the onset of labor. It is attractive to
speculate that up-regulation of functional CRH-R1s might
lead to activation of alternative signaling cascades thatmight
help in the transition of the uterus from a state of quiescence
to one of increased contractility and active labor.
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